


# ΔVΔNOS

## PAIN MANAGEMENT IN THE SURGICAL SETTING—**ARE YOU LIGHTING THE FUSE OF OPIOID ADDICTION?**

Five reasons why ON-Q\* could be your top choice for effective opioid-sparing pain relief.



# THE PROBLEM:

Over 2,000,000 patients may become persistent opioid users every year following elective, ambulatory surgery.<sup>1</sup>

- In 2016, **40%** of opioid overdose deaths involved a prescription opioid.<sup>2</sup>
- Even a **1-day** opioid prescription has been shown to pose a **6% risk** of long-term, chronic use.<sup>3</sup>
- Some non-opioid therapies have **limited duration**<sup>4-8</sup>

# THE SOLUTION:

For post-op pain management, minimizing opioid use is the new standard of care. **ON-Q\* is proven successful in all key pain management goals:**

1 CLINICAL EFFICACY

2 DURATION OF THERAPY

3 RELIABILITY

4 COST-EFFECTIVENESS

5 CUSTOMIZATION

# 1 CLINICAL EFFICACY

## ON-Q\*

ON-Q\* is indicated to **significantly reduce opioids** and provide better pain relief than opioids alone.



It has been evaluated in

**100**  
clinical studies.


## EXPAREL

Recent studies and clinical reviews of the data have concluded that **EXPAREL does NOT appear to offer additional benefits** compared to standard local anesthetics.<sup>6-7, 9-13</sup>



## 2 DURATION OF THERAPY

**ON-Q\***  
**delivers**  
**continuous**  
**relief** and  
non-opioid pain  
control for up  
to 5 days.



Clinical trial data have shown that **EXPAREL** effectively reduces pain for **up to a maximum of 24 hours**.<sup>4-7</sup>

*“Since there is not sufficient evidence supporting an advantage of [EXPAREL] over other local anesthetics, [EXPAREL] will remain on the non-promotable list and remain nonformulary.”<sup>6</sup>*

— Veteran Affairs Clinical Review of EXPAREL

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives. Bupivacaine liposome injectable suspension (EXPAREL®) update. [https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Bupivacaine\\_Liposome\\_Injectable\\_Suspension\\_EXPAREL\\_Evidence\\_Update\\_2016.pdf](https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Bupivacaine_Liposome_Injectable_Suspension_EXPAREL_Evidence_Update_2016.pdf). Published March 2016. Accessed January 25, 2018.

### 3 RELIABILITY



**ON-Q\*** has **20 years** of innovation and has been evaluated in over **100 studies** and used in over **6.4 million** patients.<sup>15</sup>



**EXPAREL uncertainty and unknowns:**

Analgesia method and dosing between study and comparator groups **may not be equivalent or reported in some EXPAREL studies.**<sup>6,14-18</sup>

For breakthrough pain, additional local anesthetics **cannot be used for up to 96 hours after administration due to potential risk of local anesthetic toxicity**<sup>19,20</sup>

Lack of published data on **lipid rescue protocols**

## 4 COST-EFFECTIVENESS

### ON-Q\*



~ **\$87.39** per day<sup>21†</sup>



Reduces length of stay by an average of **1.1 days**.<sup>22-25</sup>

### EXPAREL



~ **\$300** per day<sup>21††</sup>



Reduces length of stay by **half a day**.<sup>26</sup>

†For a CB6004 filled with .5% bupivacaine and saline mixture running for 5 days.

††Cost is ~ \$300 per vial. One vial works for up to 24 hours.

## 5 CUSTOMIZATION: EMPOWER PATIENTS WITH CUSTOMIZED PAIN CONTROL

ON-Q\* makes it easy to:



**TITRATE** MEDICATION



**TURN ON/OFF** ANALGESIA



**MONITOR EFFICACY AND SAFETY** OF PAIN MANAGEMENT FROM START TO FINISH WITH ON-Q\* TRAC

EXPAREL'S  
**"ONE SIZE FITS ALL" CAN'T BE TITRATED OR TURNED OFF<sup>27</sup>**

Patients using ON-Q\* were up to **3 times as likely to report high satisfaction scores** compared to opioids.<sup>23,25,28-31†</sup>

†Not compared with EXPAREL.

# THE CHOICE IS CLEAR.

For opioid-sparing treatment, **arm your patients with effective, long-lasting pain relief from ON-Q\***.

EXPAREL	PAIN MANAGEMENT GOALS	ON-Q*
Appears to have no benefit over standard local anesthetics <sup>6-7,9-13</sup>	CLINICAL EFFICACY	Indications for significantly reducing opioids and providing better pain relief than opioids
Pain relief for up to <b>24 hours</b> <sup>4-7</sup>	DURATION OF THERAPY	Continuous pain relief for up to <b>5 days</b>
<b>Uncertainty</b> and <b>unknowns</b> <sup>8,14-20</sup>	RELIABILITY	<b>20 years</b> of clinical experience
<b>Not titratable</b> and cannot be turned off <sup>27</sup>	CUSTOMIZATION	<b>Titratable</b> and can be turned off
~ <b>\$300</b> per day <sup>21†</sup>	COST	~ <b>\$87.39</b> per day <sup>21††</sup>

†Cost is ~ \$300 per vial. One vial works for up to 24 hours.

††For a CB6004 filled with .5% bupivacaine and saline mixture running for 5 days.



1. Brummett C, Waljee J, Goesling J, Moser S, Lin P, Englesbe M, et al. New persistent opioid use after minor and major surgical procedures in US adults. *JAMA Surg.* 2017;152(6):e170504.
2. Centers for Disease Control and Prevention. Prescription opioid overdose data. <https://www.cdc.gov/drugoverdose/data/overdose.html>. Published August 1, 2017. Accessed January 23, 2018.
3. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. *MMWR Morb Mortal Wkly Rep.* 2017;66(10):265-269.
4. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local anesthetic) in bunionectomy. *Adv Ther.* 2011;28(9):776-788.
5. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. *Dis Colon Rectum.* 2011;54(12):1552-1559.
6. VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives. Bupivacaine liposome injectable suspension (EXPAREL®) update. [https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Bupivacaine\\_Liposome\\_Injectable\\_Suspension\\_EXPAREL\\_Evidence\\_Update\\_2016.pdf](https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Bupivacaine_Liposome_Injectable_Suspension_EXPAREL_Evidence_Update_2016.pdf). Published March 2016. Accessed January 25, 2018.
7. Novitsky J, Pierce D, Whalen K, Guharoy R, Hildreth K. Bupivacaine Liposomal Versus Bupivacaine: Comparative Review. *Hosp Pharm.* 2014 Jun; 49(6): 539-543.
8. Abdallah FW, Halpern SH, Aoyama K, Brull R. Will the real benefits of single-shot interscalene block please stand up? A systematic review and meta-analysis. *Anesth Analg.* 2015;120(5):1114-1129.
9. Aljani P, Tan TL, Matthews CN, et al. Periarticular injection of liposomal bupivacaine offers no benefit over standard bupivacaine in total knee arthroplasty: a prospective, randomized, controlled trial. *J Arthroplasty.* 2017;32(2):628-634.
10. Amundson AW, Johnson RL, Abdel MP, et al. A three-arm randomized clinical trial comparing continuous femoral plus single-injection sciatic peripheral nerve blocks versus periarticular injection with ropivacaine or liposomal bupivacaine for patients undergoing total knee arthroplasty. *Anesthesiology.* 2017;126(6):1139-1150.
11. Jain RK, Porat MD, Klingenstein GG, Reid JJ, Post RE, Schoifet SD. The AAHKS clinical research award: liposomal bupivacaine and periarticular injection are not superior to single-shot intra-articular injection for pain control in total knee arthroplasty. *J Arthroplasty.* 2016;31(9 suppl):22-25.
12. DeClaire JH, Aiello PM, Warrity OK, Freeman DC. Effectiveness of bupivacaine liposome injectable suspension for postoperative pain control in total knee arthroplasty: a prospective, randomized, double blind, controlled study. *J Arthroplasty.* 2017;32(9S):S268-S271.
13. Kopp SL, Børglum J, Buvanendran A, et al. Anesthesia and analgesia practice pathway options for total knee arthroplasty: an evidence-based review by the American and European Societies of Regional Anesthesia and Pain Medicine. *Reg Anesth Pain Med.* 2017;42(6):683-697.
14. Mont MA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local infiltration analgesia with liposomal bupivacaine improves pain scores and reduces opioid use after total knee arthroplasty: results of a randomized controlled trial. *J Arthroplasty.* 2018;33(1):90-96.
15. Mulligan R, Morash J, DeOrio J, Parekh S. Liposomal Bupivacaine Versus Continuous Popliteal Sciatic Nerve Block in Total Ankle Arthroplasty. *Foot & Ankle Int.* 2017 Aug ePub:1-7.
16. Smith EB, Kazarian G, Maltenfort M, Lonner J, Sharkey P, Good R. Periarticular Liposomal Bupivacaine Injection Versus Intra-Articular Bupivacaine Infusion Catheter for Analgesia After Total Knee Arthroplasty. *J Bone Joint Surg Am.* 2017; 99:1337-44.
17. Broome CB, Burnikel B. Novel strategies to improve early outcomes following total knee arthroplasty: a case control study of intra articular injection versus femoral nerve block. *Int Orthop.* 2014 Oct;38(10):2087-9.
18. Surdam J, Licini D, Baynes N, Arce B. The Use of Exparel (Liposomal Bupivacaine) to Manage Postoperative Pain in Unilateral Total Knee Arthroplasty Patients. *Journ of Arthro.* 30 (2015) 325-329.
19. Exparel [package insert]. San Diego, CA: Pacira Pharmaceuticals, Inc.; 2016.
20. Aggarwal N. Local anesthetics systemic toxicity association with exparel (bupivacaine liposome) - a pharmacovigilance evaluation [published online ahead of print June 5, 2017]. *Expert Opin Drug* 2017:1-7. doi: 10.1080/14740338.2017.1335304.
21. Halyard data on file.
22. Forastiere E, Sofra M, Giannarelli D, Fabrizi L, Simone G. Effectiveness of continuous wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain management after open nephrectomy. *Br J Anaesth.* 2008;101(6):841-847.
23. Liu SS, Richman JM, Thirlby RC, Wu CL. Efficacy of continuous wound catheters delivering local anesthetic for postoperative analgesia: a quantitative and qualitative systematic review of randomized controlled trials. *J Am Coll Surg.* 2006;203(6):914-932.
24. White PF, Rawal S, Latham P, et al. Use of a continuous local anesthetic infusion for pain management after median sternotomy. *Anesthesiology.* 2003;99(4):918-923.
25. Beaussier M, El'Ayoubi H, Schiffer E, et al. Continuous preperitoneal infusion of ropivacaine provides effective analgesia and accelerates recovery after colorectal surgery. *Anesthesiology.* 2007;107(3):461-468.
26. Cherian JJ, Barrington JW, Mont MA. Liposomal bupivacaine suspension can reduce lengths of stay and improve discharge status of patients undergoing TKA. (Poster P132). Poster presented at: 2016 Annual Meeting of American Academy of Orthopaedic Surgeons; March 1-4, 2016; Orlando, FL.
27. Ilfeld BM. Liposome bupivacaine in peripheral nerve blocks and epidural injections to manage postoperative pain. *Expert Opin Pharmacother.* 2013;14(17):2421-2431.
28. Heller L, Kowalski AM, Wei C, Butler CE. Prospective, randomized, double-blind trial of local anesthetic infusion and intravenous narcotic patient-controlled anesthesia pump for pain management after free TRAM flap breast reconstruction. *Plast Reconstr Surg.* 2008;122(4):1010-1018.
29. Kean J, Wigderowitz CA, Coventry DM. Continuous interscalene infusion and single injection using levobupivacaine for analgesia after surgery of the shoulder: a double-blind, randomized controlled trial. *J Bone Joint Surg Br.* 2006;88(9):1173-1177.
30. Husain A, Lee GC. Establishing realistic patient expectations following total knee arthroplasty. *J Am Acad Orthop Surg.* 2015;23(12):707-713.
31. Bingham AE, Fu R, Horn JL, Abrahams MS. Continuous peripheral nerve block compared with single-injection peripheral nerve block: a systematic review and meta-analysis of randomized controlled trials. *Reg Anesth Pain Med.* 2012;37(6):583-594.

ON-Q\* TRAC is not a medical device.

There are inherent risks in all medical devices. Please refer to the product labeling for Indications, Cautions, and Warnings and Contraindications. Failure to follow the product labeling could directly impact patient safety. Physician is responsible for prescribing and administering medications per instructions provided by the drug manufacturer. Refer to [www.avanospainmanagement.com](http://www.avanospainmanagement.com) for product safety Technical Bulletins.

\*Registered Trademark or Trademark of Avanos Medical, Inc., or its affiliates. 2018 AVNS. All rights reserved. COPY-02133 09/18

# AVANOS

For more information, please visit [avanospainmanagement.com](http://avanospainmanagement.com)

1-800-448-3569

1-844-HALYARD (1-844-425-9273)

AVANOS

NON-OPIOID PAIN CONTROL THAT OUTLASTS THE COMPETITION.

ON-Q  
PAIN RELIEF SYSTEM